SC
TXG icon

Solstein Capital’s 10x Genomics TXG Stock Holding History

Solstein Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,647
Closed -$298K – 485
2021
Q1 		$298K Buy
1,647
+147
+10% +$25.4K 0.41% 74
2020
Q4 		$212 Sell
1,500
-590
-28% -$85.6K 0.09% 77
2020
Q3 		$261K Buy
+2,090
New +$219K 0.58% 48

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Solstein Capital's TXG Position: Q2 2021 in Review

Solstein Capital sold out of 10x Genomics (TXG) in Q2 2021, closing a stake of 1,647 shares — an estimated $298K sold.

Solstein Capital first reported a position in TXG in Q3 2020 and held it in 3 quarters. The position peaked at $298K in Q1 2021. 340 funds tracked by Wall St. Rank hold TXG as of Q2 2021.

  • Solstein Capital reported no remaining 10x Genomics position as of Q2 2021 after selling out during the quarter.
  • Solstein Capital sold 1,647 10x Genomics shares in Q2 2021, an estimated $298K.
  • Solstein Capital first reported a position in 10x Genomics in Q3 2020 and held it in 3 quarters.
  • Solstein Capital's 10x Genomics position peaked at $298K in Q1 2021.
  • 340 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2021.

Based on Solstein Capital's 13F filing for Q2 2021, filed 12 Aug 2021.